Business Wire

GRAFORCE

27.2.2024 01:01:32 CET | Business Wire | Press release

Share
Energy Innovation for the 21st Century: Graforce’s Plasma Technology Advances the Hydrogen Economy and CO2 Removal

Graforce is setting new standards in hydrogen production and carbon dioxide removal with its cross-cutting plasma technology (Plasmalysis). By harnessing the plasma catalytic effect, a unique property of ionized plasma, this technology significantly enhances chemical reactions' efficiency and reduces renewable power consumption by 80% compared to conventional hydrogen production methods. Plasmalysis splits natural gas and biogas into hydrogen and solid carbon, and converts ammonia or NH4-liquids into hydrogen and nitrogen.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226171060/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Graforce offers different advanced and market-ready Plasma technologies for the energy efficient production of clean hydrogen (Photo: ChatGPT)

Beyond energy efficiency, plasma decomposition of hydrocarbons opens up a new pathway for carbon dioxide removal. Converting biomethane into hydrogen and solid carbon allows for the valuable utilization of solid carbon as a byproduct. It can be sequestered in soils and building materials, thus indirectly and permanently removing CO2 from the atmosphere. With a potential CO2 reduction capacity of over 1.5 gigatons per year, roughly 3% of global greenhouse gas emissions, this technology establishes new benchmarks in the global fight against climate change.

To demonstrate the technology's potential, Graforce has built two facilities in Germany and Austria within industrial settings. Starting from May 2024, these facilities will collectively produce up to 1.2 tons of clean hydrogen daily from both natural gas and ammonia. The produced solid carbon from methane decomposition will be used to enhance agricultural soils.

Jens Hanke, founder and CEO of Graforce, emphasizes the importance of the technology: "Our plasma technology closes crucial material cycles and provides an affordable path to decarbonization, utilizing existing infrastructure and producing CO2-free heat and sustainable hydrogen, leading to a significant reduction in greenhouse gas emissions."

The broad applicability of plasma technology in areas such as hydrocarbon and ammonia splitting, synthetic methane production, and wastewater treatment underscores its role as a cross-cutting technology. It offers solutions that enhance efficiency and sustainability in key sectors like oil & gas, the chemical industry, energy generation, and mobility.

Graforce collaborates with leading companies in engineering, procurement, and construction to scale modular facilities according to customer needs. To unlock the full technical and commercial potential, Graforce is open to expanding its strategic partnerships to disseminate hydrogen technology worldwide.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240226171060/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PNCC Selects LotusFlare to Power Digital BSS and Commerce Platform for New 4G/5G Standalone Network26.2.2026 13:04:00 CET | Press release

LotusFlare, a provider of a cloud-native, AI-driven digital commerce and monetization platform for communications service providers (CSPs), today announced that Palau National Communications Corporation (PNCC) has selected it to provide a comprehensive commerce and monetization platform, including a full-stack digital business support system (dBSS) as part of PNCC’s broader 4G/5G Standalone (SA) network modernization programme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226869218/en/ Palau National Communications Corporation (PNCC) The LotusFlare solution will support PNCC subscribers across mobile, fixed broadband, and digital TV services, while enabling unique multi-tenant capabilities aligned with PNCC’s long-term digital and regional strategy. PNCC has embarked on a comprehensive technology modernization program focused on increasing speed-to-market, enhancing customer experience, and long-term operational efficie

GoldState Music and Bridgepoint Announce Strategic Partnership Targeting Growth Investments26.2.2026 13:00:00 CET | Press release

Capital will support GoldState Music’s Growth Strategy which will invest in scalable, profitable music-oriented businesses across the music value chainBridgepoint commits a significant investment as lead investor in GoldState’s Growth Strategy Bridgepoint, one of the world’s leading mid-market investors, today announced that it has entered into a strategic partnership with GoldState Music, a premier music investment platform, committing a significant investment as lead investor in GoldState’s Growth Strategy. The capital will support a dedicated investment programme focused on building and scaling high-quality music-oriented businesses globally. GoldState Music is a private investment firm founded in 2022 by industry veteran Charles Goldstuck, who played an integral role in the development of many music enterprises as well as in the careers of numerous major artists and songwriters. The company’s Growth Strategy is focused on investing in and scaling growing businesses operating in the

Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics26.2.2026 13:00:00 CET | Press release

Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market. Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small cell lung cancer (NSCLC): CL-273, a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor. John Yu, M.D., Kairos Pharma Chief Executive Officer, commented: "We anticipate this acquisition will significantly

Amazfit Introduces the Active 3 Premium: Turning Daily Movement into Meaningful Progress for Entry-Level Runners26.2.2026 13:00:00 CET | Press release

Premium materials, a 12-day battery life and new running features provide support for those kicking off their running journey Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the Amazfit Active 3 Premium, a compact, 4-button smartwatch designed as an entry point into structured running and hybrid training. Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines that combine endurance, strength, and studio-based workouts. Its compact design makes it easy to train across environments, from neighborhood runs to studio floors, offering a capable, approachable experience without feeling overbuilt or intimidating. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226378156/en/ Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines th

Wyss Geneva Spin-Off Clee Medical Secures Seed Financing to Bring Real-Time Vision to Brain Surgery26.2.2026 12:49:00 CET | Press release

The Wyss Center for Bio and Neuroengineering Geneva announced today the successful closing of the Seed financing round of Clee Medical SA, a Swiss neurotechnology spin-off developing ultra-high-resolution real-time intraoperative imaging for brain surgery. The round was led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank (ZKB), Kickfund, FONGIT, and Venture Kick joining existing investors Wyss Center Geneva. Clee Medical spun-out from Wyss Geneva’s Minimally Invasive Intracranial Access (MICA) research project in December 2024. Its flagship platform, Neuro Access, combines OCT imaging with advanced navigation to help neurosurgeons visualize brain anatomy and critical structures in real time during stereotactic procedures. “Clee Medical not only holds the promise of improving patient outcomes but also highlights Wyss Geneva’s dedication to bridging the gap between scientific discovery and real-world impact.” Dr. Erwin Böttinger, CEO, Wyss Geneva “Neurosurg

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye